Flu :: GlaxoSmithKline?s new generation flu vaccine shows a significant seroprotection
New data released today demonstrate significantly better immune responses in the age range 65 and above when vaccinated with GSK?s new generation (adjuvanted) seasonal flu vaccine compared to a traditional seasonal flu vaccine. These new data are highly important, since the disease burden and death toll is highest among the elderly in each flu season. The data, presented at the Influenza Vaccines for the World (IVW) 2006 Congress, showed the seroprotection rate (90.5%) achieved by the new adjuvanted vaccine in the elderly to be more than 25% higher than that reported in the age matched comparator group.